<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519049</url>
  </required_header>
  <id_info>
    <org_study_id>1287</org_study_id>
    <nct_id>NCT02519049</nct_id>
  </id_info>
  <brief_title>11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)</brief_title>
  <official_title>Diagnostic and Prognostic Role of 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) and Candidate to Pleurodesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective exploratory study specifically investigating the role of 11C-Methionine PET/CT
      imaging in patients affected by Malignant Pleural Mesothelioma (MPM) and candidate to
      pleurodesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label study, lasting 36 months including an estimated period of
      24 months for the enrollment and max 12 months of follow-up. All patients affected by MPM and
      referred to our Institution eligible for therapeutic pleurodesis and subsequent platinum- and
      pemetrexed-based chemotherapy will be enrolled. In all cases patients will be investigated
      with 11C-Methionine PET/CT and 18F-FDG PET/CT before talc pleurodesis, one week after and at
      the end of three cycles of chemotherapy.

      A minimum number of 20 patients will be considered for the analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing talc pleurodesis</measure>
    <time_frame>Change from Baseline in SUVmax up to 1 week after talc pleurodesis.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mesothelioma, Malignant</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is an observational study</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy specimen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients affected by MPM and referred to our Institution for therapeutic pleurodesis
        and subsequent platinum- and pemetrexed-based chemotherapy will be enrolled. A minimum
        number of 20 patients will be considered for the analysis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with an histological diagnosis of MPM eligible for pleurodesis and scheduled
             to undergo platinum- and pemetrexed-based chemotherapy.

          -  obtained informed consent

        Exclusion Criteria:

          -  patients age &lt;18 years

          -  pregnancy or breast-feeding;

          -  patients affected by other malignancies within the last 3 years;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egesta Lopci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Clinical and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Egesta Lopci, MD</last_name>
    <phone>+39 0282247542</phone>
    <email>egesta.lopci@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Zucali, MD</last_name>
    <phone>+39 0282244061</phone>
    <email>paolo.zucali@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egesta Lopci, MD</last_name>
      <phone>+39 0282247542</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, Lorenzi E, Gemelli M, Santoro A, Chiti A. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):667-75. doi: 10.1007/s00259-014-2960-y. Epub 2014 Nov 18.</citation>
    <PMID>25403555</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Chiti A, Zucali PA, Cappuzzo F, De Vincenzo F, Cavina R, Rodari M, Poretti D, Lutman FR, Santoro A. Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev. 2007 Oct;33(6):533-41. Epub 2007 Aug 30. Review.</citation>
    <PMID>17764849</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Chiti A, Santoro A. 11C-labeled methionine and evaluation of malignant pleural mesothelioma. N Engl J Med. 2007 Nov 8;357(19):1982-4.</citation>
    <PMID>17989397</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesothelioma</keyword>
  <keyword>11C-methionine PET</keyword>
  <keyword>talc pleurodesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

